Skip to main content
. 2020 Sep 11;11(9):741. doi: 10.1038/s41419-020-02967-z

Fig. 3. LIN28B-AS1 KO inhibits HCC cell progression in vitro.

Fig. 3

Total RNA was extracted from the stable HepG2 cells or primary human HCC cells (“HCC1”) with CRISPR/Cas9-LIN28B-AS1-KO construct (“KO-LIN28B-AS1”) or CRISPR/Cas9 control construct (“CRISPR-C”), expression of LIN28B-AS1 a, h, Gli1, Myc and IGF2 mRNA/protein b, i were tested. Cells were further cultured for applied time periods, cell survival, proliferation, migration, invasion as well as cell apoptosis and mitochondrial depolarization were tested by the assays mentioned, and results were quantified cg, j, k. Listed proteins were quantified and normalized b. Data were presented as mean ± standard deviation (SD, n = 5). *p < 0.05 vs. “CRISPR-C” cells. The experiments were repeated three times, and similar results were obtained.